MX2021005273A - Inhibidores de quinasa rock. - Google Patents
Inhibidores de quinasa rock.Info
- Publication number
- MX2021005273A MX2021005273A MX2021005273A MX2021005273A MX2021005273A MX 2021005273 A MX2021005273 A MX 2021005273A MX 2021005273 A MX2021005273 A MX 2021005273A MX 2021005273 A MX2021005273 A MX 2021005273A MX 2021005273 A MX2021005273 A MX 2021005273A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- compounds
- methods
- present
- rock kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos que inhiben la actividad de ROCK; en particular, la presente invención se refiere a compuestos, composiciones farmacéuticas y métodos de uso, tales como métodos para inhibir la actividad ROCK y métodos para tratar, por ejemplo, el síndrome de malformación cavernosa cerebral (CCM) y enfermedades cardiovasculares usando los compuestos y composiciones farmacéuticas de la presente invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862756202P | 2018-11-06 | 2018-11-06 | |
PCT/US2019/059992 WO2020097158A1 (en) | 2018-11-06 | 2019-11-06 | Rock kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021005273A true MX2021005273A (es) | 2021-09-08 |
Family
ID=70459339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021005273A MX2021005273A (es) | 2018-11-06 | 2019-11-06 | Inhibidores de quinasa rock. |
Country Status (13)
Country | Link |
---|---|
US (1) | US10745381B2 (es) |
EP (1) | EP3877364A4 (es) |
JP (1) | JP2022506572A (es) |
KR (1) | KR20210093269A (es) |
CN (1) | CN113227054A (es) |
AU (1) | AU2019377087A1 (es) |
BR (1) | BR112021008883A2 (es) |
CA (1) | CA3118738A1 (es) |
EA (1) | EA202191164A1 (es) |
IL (1) | IL282941A (es) |
MX (1) | MX2021005273A (es) |
SG (1) | SG11202104446UA (es) |
WO (2) | WO2020097158A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113582926B (zh) * | 2021-09-09 | 2022-03-01 | 安徽有吉医药科技有限公司 | 4-氟异喹啉-5-磺酰氯或其药学上可接受的盐的合成方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7049468B2 (en) * | 2001-11-19 | 2006-05-23 | Iconix Pharmaceuticals, Inc. | Modulators of Rho C activity |
US20040266755A1 (en) | 2003-05-29 | 2004-12-30 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
ATE423779T1 (de) * | 2005-04-25 | 2009-03-15 | Western Therapeutics Inst Inc | Hochselektiver rho-kinase-inhibitor |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
CA2926478C (en) | 2012-10-05 | 2022-05-24 | Kadmon Corporation, Llc | Rho kinase inhibitors |
FR3017868A1 (fr) * | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP6581111B2 (ja) * | 2014-04-28 | 2019-09-25 | メッドシャイン ディスカバリー インコーポレイテッド | Rhoキナーゼ阻害剤としてのイソキノリンスルホン誘導体 |
US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
US10149856B2 (en) | 2015-01-26 | 2018-12-11 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
TWI699207B (zh) * | 2015-08-31 | 2020-07-21 | 日商興和股份有限公司 | 拉巴斯吉之用於製造眼壓下降增強劑之用途 |
KR102473481B1 (ko) | 2016-07-07 | 2022-12-01 | 브리스톨-마이어스 스큅 컴퍼니 | 강력하고 선택적인 rock 억제제로서의 락탐, 시클릭 우레아 및 카르바메이트, 및 트리아졸론 유도체 |
CN109661396B (zh) | 2016-07-07 | 2022-07-01 | 百时美施贵宝公司 | 作为rock抑制剂的螺稠合环状脲 |
JP7113810B2 (ja) | 2016-07-07 | 2022-08-05 | ブリストル-マイヤーズ スクイブ カンパニー | Rock阻害剤としてのスピロラクタム |
JP7117306B2 (ja) * | 2016-12-21 | 2022-08-12 | バイオアクソン バイオサイエンシーズ インコーポレイテッド | Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物 |
JP7234201B2 (ja) | 2017-07-12 | 2023-03-07 | ブリストル-マイヤーズ スクイブ カンパニー | 心不全の治療のためのrockの5員アミノヘテロ環および5,6-または6,6員二環式アミノヘテロ環の阻害剤 |
US11447487B2 (en) | 2017-07-12 | 2022-09-20 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as rock inhibitors |
TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
KR102680164B1 (ko) | 2017-07-12 | 2024-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | Rock 억제제로서의 페닐아세트아미드 |
-
2019
- 2019-11-06 JP JP2021523997A patent/JP2022506572A/ja active Pending
- 2019-11-06 WO PCT/US2019/059992 patent/WO2020097158A1/en unknown
- 2019-11-06 MX MX2021005273A patent/MX2021005273A/es unknown
- 2019-11-06 KR KR1020217016686A patent/KR20210093269A/ko unknown
- 2019-11-06 US US16/676,044 patent/US10745381B2/en active Active
- 2019-11-06 CN CN201980085629.1A patent/CN113227054A/zh active Pending
- 2019-11-06 BR BR112021008883-0A patent/BR112021008883A2/pt unknown
- 2019-11-06 EA EA202191164A patent/EA202191164A1/ru unknown
- 2019-11-06 CA CA3118738A patent/CA3118738A1/en active Pending
- 2019-11-06 EP EP19881800.7A patent/EP3877364A4/en active Pending
- 2019-11-06 AU AU2019377087A patent/AU2019377087A1/en active Pending
- 2019-11-06 SG SG11202104446UA patent/SG11202104446UA/en unknown
-
2020
- 2020-05-05 WO PCT/US2020/031428 patent/WO2021091593A1/en active Application Filing
-
2021
- 2021-05-05 IL IL282941A patent/IL282941A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2019377087A1 (en) | 2021-06-03 |
JP2022506572A (ja) | 2022-01-17 |
EP3877364A1 (en) | 2021-09-15 |
CN113227054A (zh) | 2021-08-06 |
US20200140412A1 (en) | 2020-05-07 |
EA202191164A1 (ru) | 2022-01-24 |
EP3877364A4 (en) | 2022-08-03 |
WO2020097158A1 (en) | 2020-05-14 |
IL282941A (en) | 2021-06-30 |
KR20210093269A (ko) | 2021-07-27 |
BR112021008883A2 (pt) | 2021-08-10 |
WO2021091593A1 (en) | 2021-05-14 |
US10745381B2 (en) | 2020-08-18 |
SG11202104446UA (en) | 2021-05-28 |
CA3118738A1 (en) | 2020-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA033343B1 (ru) | Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой | |
MX2022002465A (es) | Inhibidores de kras g12d. | |
PH12020550622A1 (en) | Kras g12c inhibitors | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
MX2021015106A (es) | Inhibidores de ferroportina novedosos. | |
MX2023004593A (es) | Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. | |
MX2022002938A (es) | Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta). | |
PH12017501925A1 (en) | Pyrazole compounds and method for making and using the compounds | |
SA517390509B1 (ar) | مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليه | |
MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
EA033163B1 (ru) | Ингибиторы глутаминазы | |
PH12016501160A1 (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
PH12018500423A1 (en) | Inhibitors of ezh2 | |
MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
GEP20227442B (en) | Boron containing pde4 inhibitors | |
MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
MX2017014752A (es) | Nuevos etinos de amidoheteroaril aroil hidrazida. | |
MX2021005273A (es) | Inhibidores de quinasa rock. | |
MX2023001721A (es) | Combinacion de regonafenib e inhibidores de pd-1/pd-l1(2) para el tratamiento contra el cancer. | |
MX2020010577A (es) | Derivados de morfolina como inhibidores de vps34. | |
EA201792676A1 (ru) | Ингибиторы jak1 |